Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
Resistance training and walking can be beneficial for patients with multiple myeloma.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.
Real-World Experiences With Teclistamab Are Comparable To Clinical Trial Reports
In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.
Nurse-Developed Algorithm Helps Identify Pneumocystis Pneumonia Risk
The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.
Pegfilgrastim Plus Plinabulin May Help Mitigate Neutropenia Risk in Patients With Myeloma
Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.
Real-world Data Highlight Daratumumab Compliance Rates in MM Patients
Findings of a retrospective analysis of patients with multiple myeloma showed that the median duration of treatment with daratumumab was 16.6 months.
Optimizing QOL Assessments Requires Multiple Patient-Reported Outcomes Measures
There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.
Ocular Visits Are a Necessity for Patients With Multiple Myeloma Who Receive Belantamab Mafodotin
A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.
Verina Underscores Best Nursing Practices With Targeted Therapies in Multiple Myeloma
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.
Oral and Dermatologic Toxicities Associated With Talquetamab Can Be Mitigated With Nurse Intervention
Through patient education tactics, oncology nurses can help patients with multiple myeloma mitigate the oral and dermatologic toxicities associated with talquetamab.
Minimal Residual Disease May Anticipate Outcomes in Myeloma Following Stem Cell Transplant
Patients with myeloma and a negative MRD may be at a reduced risk of mortality and other progression-free survival events.
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
Chemo Should be Tailored to Decrease Neuropathy in Black Patients
NT-I7 Enhances CAR T-Cell Efficacy in DLBCL
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd